Cochrane Systematic Review: Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections
Schuetz P, Mller B, Christ-Crain M, Stolz D, Tamm M, Bouadma L, Luyt CE, Wolff M, Chastre J, Tubach F, Kristoffersen KB, Burkhardt O, Welte T, Schroeder S, N...
Schuetz P, Mller B, Christ-Crain M, Stolz D, Tamm M, Bouadma L, Luyt CE, Wolf...
Objectives: The aim of this systematic review based on individual patient data was to assess the safety and efficacy of using procalcitonin for starting or stopping antibiotics over a large range of patients with varying severity of ARIs and from different clinical settings.
Objectives: The aim of this systematic review based on individual patient data was to assess the safety and efficacy of using procalcitonin for starting or stopping antibiotics over a large range of patients with varying severity of ARIs and from different clinical settings.
Cochrane Systematic Review: Rapid viral diagnosis for acute febrile respiratory illness in children in the Emergency Department
Doan Q, Enarson P, Kissoon N, Klassen TP, Johnson DW.
Doan Q, Enarson P, Kissoon N, Klassen TP, Johnson DW.
Objectives: To determine the effect of rapid viral testing in the ED on the rate of precautionary testing, antibiotic use, and length of ED visit.
Objectives: To determine the effect of rapid viral testing in the ED on the rate of precautionary testing, antibiotic use, and length of ED visit.
Cochrane Systematic Review: Macrolide antibiotics for cystic fibrosis
Southern KW, Barker PM, Solis-Moya A, Patel L
Southern KW, Barker PM, Solis-Moya A, Patel L
OBJECTIVES: To test the hypotheses that, in people with cystic fibrosis, macrolide antibiotics: 1. improve clinical status compared to placebo or another antibiotic; 2. do not have unacceptable adverse effects. If benefit was demonstrated, we aimed to assess the optimal type, dose and duration of macrolide therapy.
OBJECTIVES: To test the hypotheses that, in people with cystic fibrosis, macrolide antibiotics: 1. improve clinical status compared to placebo or another antibiotic; 2. do not have unacceptable adverse effects. If benefit was demonstrated, we aimed to assess the optimal type, dose and duration of macrolide therapy.
Cochrane Systematic Review: Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis
Hurley MN, Forrester DL, Smyth AR
Hurley MN, Forrester DL, Smyth AR
OBJECTIVES: To determine if antibiotic adjuvants improve clinical and microbiological outcome of pulmonary infection in people with cystic fibrosis.
OBJECTIVES: To determine if antibiotic adjuvants improve clinical and microbiological outcome of pulmonary infection in people with cystic fibrosis.
Cochrane Systematic Review: Antibiotics for otitis media with effusion in children
van Zon A, van der Heijden GJ, van Dongen TM, Burton MJ, Schilder AG
van Zon A, van der Heijden GJ, van Dongen TM, Burton MJ, Schilder AG
OBJECTIVES: To assess the effects of antibiotics in children up to 18 years with OME.
OBJECTIVES: To assess the effects of antibiotics in children up to 18 years with OME.
Cochrane Systematic Review: Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections
Schuetz P, Mller B, Christ-Crain M, Stolz D, Tamm M, Bouadma L, Luyt CE, Wolff M, Chastre J, Tubach F, Kristoffersen KB, Burkhardt O, Welte T, Schroeder S, N...
Schuetz P, Mller B, Christ-Crain M, Stolz D, Tamm M, Bouadma L, Luyt CE, Wolf...
Objectives: The aim of this systematic review based on individual patient data was to assess the safety and efficacy of using procalcitonin for starting or stopping antibiotics over a large range of patients with varying severity of ARIs and from different clinical settings.
Objectives: The aim of this systematic review based on individual patient data was to assess the safety and efficacy of using procalcitonin for starting or stopping antibiotics over a large range of patients with varying severity of ARIs and from different clinical settings.
Cochrane Systematic Review: Rapid viral diagnosis for acute febrile respiratory illness in children in the Emergency Department
Doan Q, Enarson P, Kissoon N, Klassen TP, Johnson DW.
Doan Q, Enarson P, Kissoon N, Klassen TP, Johnson DW.
Objectives: To determine the effect of rapid viral testing in the ED on the rate of precautionary testing, antibiotic use, and length of ED visit.
Objectives: To determine the effect of rapid viral testing in the ED on the rate of precautionary testing, antibiotic use, and length of ED visit.
Cochrane Systematic Review: Macrolide antibiotics for cystic fibrosis
Southern KW, Barker PM, Solis-Moya A, Patel L
Southern KW, Barker PM, Solis-Moya A, Patel L
OBJECTIVES: To test the hypotheses that, in people with cystic fibrosis, macrolide antibiotics: 1. improve clinical status compared to placebo or another antibiotic; 2. do not have unacceptable adverse effects. If benefit was demonstrated, we aimed to assess the optimal type, dose and duration of macrolide therapy.
OBJECTIVES: To test the hypotheses that, in people with cystic fibrosis, macrolide antibiotics: 1. improve clinical status compared to placebo or another antibiotic; 2. do not have unacceptable adverse effects. If benefit was demonstrated, we aimed to assess the optimal type, dose and duration of macrolide therapy.
Cochrane Systematic Review: Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis
Hurley MN, Forrester DL, Smyth AR
Hurley MN, Forrester DL, Smyth AR
OBJECTIVES: To determine if antibiotic adjuvants improve clinical and microbiological outcome of pulmonary infection in people with cystic fibrosis.
OBJECTIVES: To determine if antibiotic adjuvants improve clinical and microbiological outcome of pulmonary infection in people with cystic fibrosis.
Cochrane Systematic Review: Antibiotics for otitis media with effusion in children
van Zon A, van der Heijden GJ, van Dongen TM, Burton MJ, Schilder AG
van Zon A, van der Heijden GJ, van Dongen TM, Burton MJ, Schilder AG
OBJECTIVES: To assess the effects of antibiotics in children up to 18 years with OME.
OBJECTIVES: To assess the effects of antibiotics in children up to 18 years with OME.